TREATMENT OF ATRIAL FIBRILLATION BY MEANS OF VIDARABINE

Title:

TREATMENT OF ATRIAL FIBRILLATION BY MEANS OF VIDARABINE

Document Type and Number:

WIPO Patent Application WO/2013/051330

Kind Code:

A1

Abstract:

Provided is a novel antiarrhythmic agent. An antiarrhythmic agent containing vidarabine, and a pharmaceutically accepted salt or solvate thereof.

More Like This:

WO/2018/133835	NUCLEOSIDE ANALOGUE REGULATING MAMMALIAN CIRCADIAN RHYTHM
WO/2023/095860	COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG
JP2017125021	DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK, AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME

Inventors:

ISHIKAWA YOSHIHIRO (JP)
OKUMURA SATOSHI (JP)
SUITA KENJI (JP)

Application Number:

PCT/JP2012/069540

Publication Date:

April 11, 2013

Filing Date:

August 01, 2012

Export Citation:

Click for automatic bibliography generation Help

Assignee:

PUBLIC UNIV CORP YOKOHAMA CITY (JP)
ISHIKAWA YOSHIHIRO (JP)
OKUMURA SATOSHI (JP)
SUITA KENJI (JP)

International Classes:

A61K31/7076; A61P9/06; A61P43/00

Domestic Patent References:

WO2012056976A1

2012-05-03

Foreign References:

JP2002338467A

2002-11-27

Other References:

IWATSUBO,K. ET AL.: "Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration", J BIOL CHEM, vol. 279, 2004, pages 40938 - 45, XP002525724, DOI: doi:10.1074/JBC.M314238200
IWATSUBO,K. ET AL.: "Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling", ENDOCR METAB IMMUNE DISORD DRUG TARGETS, vol. 6, 2006, pages 239 - 47

Attorney, Agent or Firm:

MAYAMA, Setsuko et al. (JP)
Setsuko Mayama (JP)

Download PDF:

View/Download PDF PDF Help

Claims:

Previous Patent: METHOD FOR MANUFACTURING SOLAR CELL

Next Patent: MANUAL POWER GENERATION DEVICE FOR DRIVING ACTUATOR, AND ACTUATOR DRIVE DEVICE